Track PLSE and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$2.04B
Enterprise Value$2.03B
Revenue (TTM)$1.18M
Net Income (TTM)-$72.78M
Free Cash Flow (TTM)-$54.44M
Financial Health
Cash$80.73M
Net Debt-$14.16M
Debt Ratio0.69
Debt to Equity0.83
Interest Coverage-
Valuation (TTM)
Price to Sales1725.37
Price to Earnings-28.02
EV to EBITDA-27.76
Price to Book25.28
Price to Free Cash Flow-37.46
Margins (TTM)
Gross Profit Margin-84.43%
EBITDA Margin-6173.01%
Operating Income Margin-6509.22%
Net Income Margin-6157.45%
Free Cash Flow Margin-4605.50%
Returns (5Y Avg)
Return on Invested Capital-93.76%
Return on Assets-86.02%
Return on Equity442.69%
Return on Total Capital-93.76%
Return on Capital Employed-86.97%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue23.89%
Diluted EPS11.88%
Total Debt23.70%
Capital Expenditures-6.51%
Free Cash Flow-65.10%
CAGR (3Y)
Revenue-20.30%
Diluted EPS14.56%
Total Debt-71.36%
Capital Expenditures-7.73%
Free Cash Flow-99.48%
CAGR (1Y)
Revenue1000.00%
Diluted EPS-13.96%
Total Debt15.87%
Capital Expenditures152.00%
Free Cash Flow-100.00%
$32.76+$2.50|+7.63%
Last updated: Jul 22, 4:00 PM ET
52W High$31.00
52W Low$12.56
50D SMA$26.00
200D SMA$19.79
Volume591.78K
Pulse Biosciences Inc
601 Brickell Key Drive, Miami, FL, United States, 33131
IPO
2016
Employees
116
Industry
Medical Instruments & Supplies
Sector
Healthcare
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20265-5
0
Q4 20251-1
0
Q3 20255-4
1
Q2 20251-1
0
4-quarter cumulative
12 sells1 buys
Analyst Ratings
No coverage data
No analyst ratings data available